Cited by 823Genetic Associations and EpidemiologyAtherosclerosis and Cardiovascular DiseasesAdipokines, Inflammation, and Metabolic Diseases

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

Open access
‡·2012·The Lancet

Abstract

Background Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades. To assess whether this pathway is causally relevant to coronary heart disease, we studied a functional genetic variant known to affect IL6R signalling.Methods In a collaborative meta-analysis, we studied Asp358Ala (rs2228145) in IL6R in relation to a panel of conventional risk factors and inflammation biomarkers in 125,222 participants. We also compared the frequency of Asp358Ala in 51,441 patients with coronary heart disease and in 136,226 controls. To gain insight into possible mechanisms, we assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.Findings The minor allele frequency of Asp358Ala was 39%. Asp358Ala was not associated with lipid concentrations, blood pressure, adiposity, dysglycaemia, or smoking (p value for association per minor allele ≥0·04 for each). By contrast, for every copy of 358Ala inherited, mean concentration of IL6R increased by 34·3% (95% CI 30·4-38·2) and of interleukin 6 by 14·6% (10·7-18·4), and mean concentration of C-reactive protein was reduced by 7·5% (5·9-9·1) and of fibrinogen by 1·0% (0·7-1·3). For every copy of 358Ala inherited, risk of coronary heart disease was reduced by 3·4% (1·8-5·0). Asp358Ala was not related to IL6R mRNA levels or interleukin-6 production in monocytes.Interpretation Large-scale human genetic and biomarker data are consistent with a causal association between IL6R-related pathways and coronary heart disease.Funding British Heart Foundation; UK Medical Research Council; UK National Institute of Health Research, Cambridge Biomedical Research Centre; BUPA Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)61931-4

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease.

    “genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”

    From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [24]

    The Discussion reports genetic and biomarker evidence consistent with a causal association between IL6R-related pathways and coronary heart disease. The claim broadens that finding from IL6R pathways to IL-6 itself and from coronary heart disease to atherosclerotic cardiovascular disease generally; the Discussion identifies non-coronary outcomes as a subject for future study. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [45]Genovese MC Smolen JS Emery P Analysis of low-density lipoprotein and adverse events in rheumatoid arthritis patients treated with tocilizumab plus statins: data from five phase III clinical trials Rheumatology (Oxford) 48 2009 I81 (abstr 175).

Cited by

Sorted by citations

Authors
‡
Affiliations
University of Cambridge (GB)
Corresponding author
‡
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-03
Volume
379
Issue
9822
Pages
1205-1213
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2139957955
Cited by
823
References
47
Citations by year
2026: 48 · 2025: 46 · 2024: 63 · 2023: 46 · 2022: 50 · 2021: 69 · 2020: 73 · 2019: 57 · 2018: 61 · 2017: 60 · 2016: 58 · 2015: 48 · 2014: 72 · 2013: 48 · 2012: 23
FWCI
7.54
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • UnissResearch (Università degli Studi di Sassari) (submittedVersion)
  • Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • Site cant be reached (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
Funders
  • British Heart Foundation (RG/08/014)
  • Bupa Foundation
  • Medical Research Council
  • NIHR Cambridge Biomedical Research Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
IL-6 receptor, coronary artery disease, rs2228145, genetic association, inflammation, C-reactive protein, fibrinogen, interleukin-6, chronic inflammation, cardiovascular risk factors, monocytes, gene expression
MeSH terms
Coronary Disease, Gene Frequency, Humans, Risk Factors, Genetic Variation, Signal Transduction, Causality, Inflammation Mediators, Receptors, Interleukin-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review